What the JMIR Clinical Support Gap Study Actually Found About Lean Mass Loss
A May 2026 retrospective cohort study in J Med Internet Res found patients receiving GLP-1 medications through telehealth without nutritional support lost up to 40% of their weight loss as lean muscle. Here's what the data shows and what its limitations mean.
A May 2026 study published in the Journal of Medical Internet Research quantified a specific risk associated with GLP-1 medication use without dietitian support: patients who received their medication through telehealth without structured nutritional guidance lost up to 40% of their weight loss as lean muscle mass, compared to approximately 25% in patients with dietitian involvement.
Study Design
The retrospective cohort study (J Med Internet Res 2026;28:e101874) analyzed body composition data from 1,247 patients across three cohorts: patients receiving GLP-1 medications through traditional clinical care with dietitian support, patients using telehealth platforms that included structured nutritional counseling, and patients using telehealth platforms with prescription-only service and no nutritional component.
Primary outcome: ratio of lean mass loss to total weight loss at 6 months and 12 months, measured by DEXA scan in a subset (n=312) and by validated bioelectrical impedance analysis in the remainder.
Key Findings
| Cohort | Lean mass % of total loss (6mo) | Lean mass % of total loss (12mo) |
|---|---|---|
| Traditional care + dietitian | 24.2% | 22.8% |
| Telehealth + structured nutrition | 26.1% | 25.3% |
| Telehealth, no nutrition support | 37.4% | 39.8% |
Why This Matters: The Lean Mass Gap
The clinical significance of lean mass preservation has grown as GLP-1 prescribing has scaled. Several considerations:
Metabolic rate: lean mass is metabolically active tissue. Disproportionate lean mass loss reduces basal metabolic rate, which increases the risk of weight regain after medication discontinuation — a concern that has already been documented in GLP-1 extension studies.
Physical function: especially relevant in older adults, lean mass loss impairs strength, mobility, and fall risk. GLP-1 prescribing in adults over 60 without lean mass protection creates a specific functional vulnerability.
The SURMOUNT-4 context: the 2024 SURMOUNT-4 extension trial documented substantial weight regain after tirzepatide discontinuation. The lean mass profile during treatment likely contributes to the regain trajectory — patients who preserved more lean mass regained less.
The study found that patients in the telehealth-without-support cohort consumed significantly less protein than the other groups — averaging 0.6g per kg body weight versus 1.1g per kg in the traditional care group. The protein gap, not just the absence of a dietitian appointment, appears to be the mechanistic driver of the lean mass difference.
Limitations
The retrospective design cannot establish causation — patients who sought traditional care with dietitian support may differ systematically from those using prescription-only telehealth in ways that affect body composition outcomes independently of nutritional support. DEXA confirmation was only available for a subset. The 12-month follow-up rate was 64% in the telehealth cohorts, introducing potential dropout bias if patients who lost more lean mass were more likely to discontinue.
Looking for a GLP-1 provider?
Our sister site independently compares compounding pharmacies and telehealth platforms —
no sponsored placements.
Sources
- Marano CM, et al. "Lean Mass Preservation in GLP-1 Receptor Agonist Therapy: A Retrospective Cohort Analysis of Telehealth vs. Traditional Care Models." J Med Internet Res 2026;28:e101874.
- Wilding JPH, et al. "Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide." Lancet. 2022.
- Garvey WT, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nat Med. 2022.